先通医药港股IPO及境内未上市股份“全流通”获中国证监会备案

Core Insights - The China Securities Regulatory Commission (CSRC) has issued a notice regarding Beijing Xiantong International Pharmaceutical Technology Co., Ltd.'s overseas issuance and the "full circulation" of unlisted shares in the domestic market, allowing the company to issue up to 9,259,900 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange [1] - Xiantong Pharmaceutical is a leader in China's radiopharmaceutical market, focusing on the development and commercialization of innovative radiopharmaceuticals, aiming to be the first listed company in China with unique or best-in-class potential in this field [1] - The company is recognized as the first in China to obtain approval for innovative radiopharmaceuticals, hold production licenses as a Marketing Authorization Holder (MAH), and complete clinical trials for therapeutic radioligands [1] Company Overview - Xiantong Pharmaceutical plans to convert a total of 34,466,214 unlisted shares held by 95 shareholders into overseas listed shares for trading on the Hong Kong Stock Exchange [1] - The company is positioned as a pioneer in the innovative radiopharmaceutical sector, with significant achievements in regulatory approvals and clinical trials [1] Shareholder Details - A detailed list of shareholders and the number of shares they plan to convert to full circulation has been provided, with notable shareholders including Xu Xingsheng (3,343,071 shares) and Jiangsu Jiequan Chengda Equity Investment Center (2,959,381 shares) [2][3]